The supplementary protection certificate of the US pharma company Gilead, which covers the active agent combination of the HIV medicament TRUVADA®, was nullified by the German Federal Patent Court (file no. 4 NI 12/17). Maiwald successfully represented the British generic producer Generics [UK] Ltd. in the nullity proceedings.
The complete article can be downloaded here: http://thespcblog.blogspot.com/2018/05/germany-gileads-spc-for-truvada.html
